MRI Biomarkers of breast cancer complete pathologic response to neoadjuvant chemotherapy
Elizabeth Jane Sutton1, Duc A. Fehr2, Brittany Z. Dashevsky1,3, Sunitha B Thakur2, Joseph O. Deasy2, Elizabeth A Morris1, and Harini Veeraraghavan2
1Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States, 2Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, United States, 3Radiology, University of Chicago, Chicago, IL, United States
Neoadjuvant
chemotherapy (NAC) is used in breast cancer and pathologic complete response
(pCR) is associated with improved survival. Computer extracted MRI features
generate quantitative metrics of treatment response. We used an
interactive Grow-Cut method to volumetrically
segment breast cancers on multiparametric breast MRI pre and post NAC and
then computed Haralick features for each sequence. We found a difference in the MRI tumor texture
features pre and post NAC. We also found this difference to be statistically
significant between tumors with pCR and no-pCR. These metrics demonstrate changes
in tumor microenvironment post NAC and are biomarkers for pCR.
This abstract and the presentation materials are available to members only;
a login is required.
